You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


EU green lights AZ, MSD’s rare disease therapy Koselugo

The European Commission (EC) has granted AstraZeneca (AZ) and MSD’s Koselugo (selumetinib) a conditional approved for the treatment of children with symptomatic, inoperable plexiform neurofibromas (PN) and neurofibromatosis type 1 (NF1).